Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: Connection refused in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa sales

besponsa sales

Перейти к контенту

Главное меню:

Разное
besponsa sales
Welcome to BESPONSA® | BESPONSA®, NICE to reassess Pfizer’s leukaemia drug Besponsa , US regulators approve Pfizer's Besponsa in ALL - Pharmaphorum, Pfizer's Besponsa Is Yet Another Win for the Biopharma , Besponsa | European Medicines Agency, NICE rejects Pfizer’s ALL drug Besponsa - PharmaTimes, Besponsa (inotuzumab) - Pfizer Sales History and Forecasts , Global Besponsa Market 2018 by Manufacturers, Regions , About BESPONSA® | BESPONSA®.
BESPONSA can cause liver problems that can be severe, life-threatening, or fatal, including a condition called veno-occlusive disease (VOD). This condition can occur during treatment with BESPONSA or following subsequent treatment with a stem cell transplant. This condition was more common in patients who had elevated liver tests or who received dual alkylating agents in preparation for their stem cell transplant. Patients may be at a higher risk of VOD if they: . 81% (88/109) of patients achieved remission * with BESPONSA compared to 29% (32/109) of patients with chemotherapy * Remission means that no leukemia cells can be seen when looking at bone marrow under a microscope.. Besponsa is an antibody drug conjugate comprised of a monoclonal antibody targeting CD22, a cell surface antigen expressed on around 90 percent of B-cell malignancies, linked to a cytotoxic agent. When the drug binds to CD22 on malignant B-cells it is taken into the cell, where the cytotoxic agent calicheamicin is released to destroy it..
Besponsa (inotuzumab ozogamicin) is the first of its kind to be indicated for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia.. Besponsa isn't going to be the company's best-selling cancer drug, but its sales should still contribute to Pfizer regaining its growth momentum. This year, Pfizer expects sales of between $52 . Besponsa is a cancer medicine used to treat a type of blood cancer which affects B cells (a type of white blood cells) called B-cell precursor acute lymphoblastic leukaemia (ALL).. Besponsa (inotuzumab) is an antibody drug conjugate which is comprised of a monoclonal antibody targeting CD22, a cell surface antigen expressed on around 90 percent of B-cell malignancies, linked to a cytotoxic agent.. Besponsa is an Anti-CD22 mAb (small molecule) with an indication for ALL - Acute Lymphoblastic Leukaemia.. Chapter 2, to analyze the top manufacturers of Besponsa, with sales, revenue, and price of Besponsa, in 2016 and 2017; Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;.
 
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню